Dengue Vaccination Strategy EvaluationNCT07206784
Understanding the Public Impact on Dengue Vaccination Strategies in Yunnan Province, China: A Dynamic Transmission Modeling Study
An observational study of Dengue Vaccination Strategy Evaluation and Transmission Modeling of Dengue, run by Fudan University at 1 site in China.
Trial summary
This study is a collaboration between the School of Public Health at Fudan University and the Xishuangbanna Center for Disease Control and Prevention in Yunnan Province, China. It aims to evaluate the public health impact of dengue vaccination strategies using dynamic transmission models. Read more about this study
- Who is it for?
- Ages 3 years and older
- Conditions the study is for
- Dengue Vaccination Strategy Evaluation, Transmission Modeling of Dengue, Public Health Impact of Vaccination
- How many people
- 220 participants
- Where
- 1 siteChina
- Study dates
- 1 May 2025to 1 May 2027
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 3 years and older
- All sexes
- Child, Adult, Older adult
Study population: Residents of Jinghong City, Xishuangbanna Prefecture, aged 3 years and older, selected across eight age groups for serological investigation of dengue virus exposure.
Who may be able to join
- Resident of Jinghong City, Xishuangbanna Prefecture
- Aged 3 years and above
- Able and willing to provide informed consent (or have legal guardian consent for minors)
- Available for blood sample collection between May and August 2025
Who cannot join
- Individuals with bleeding disorders or other contraindications to blood draw
- Individuals currently diagnosed with acute dengue infection
Trial locations and contacts
1 site in 1 country.
China1 site
Xishuangbanna Center for Disease Control and Prevention
Jinghong, Yunnan
About this study
This study is a collaboration between the School of Public Health at Fudan University and the Xishuangbanna Center for Disease Control and Prevention in Yunnan Province, China. It aims to evaluate the public health impact of dengue vaccination strategies using dynamic transmission models. By simulating different vaccination scenarios, the study will assess the potential effectiveness and public health benefits of dengue vaccine introduction, providing scientific evidence to support local dengue prevention and control efforts.
What is being measured
The primary outcome is the main question the study is designed to answer.
Dengue Virus Serological Response (IgM and IgG Antibody Levels)
Measured: From blood sample collection to the completion of laboratory analysis of dengue serology, serotype identification, and whole genome sequencing, from May to August 2025
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted3 Oct 2025
- Study start1 May 2025
- Primary completion1 May 2026
- Study completion1 May 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Dengue Vaccination Strategy EvaluationStudies of the same condition, open and under way.
- More trials run by Fudan UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Ecologic or community
- Time perspective
- Cross-sectional
- Enrolment
- 220 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Fudan University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Yao, Ye, Fudan University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07206784
- Sponsor's protocol ID
- IRB00002408 & FWA00002399
- Status last verified
- Sep 2026
- First submitted
- 26 Sep 2025
- Last updated
- 9 Sep 2026
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 9 Sep 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Understanding the Public Impact on Dengue Vaccination Strategies in Yunnan Province, China: A Dynamic Transmission Modeling Study
- ClinicalTrials.gov ID
- NCT07206784
- Acronym / sponsor ID
- IRB00002408 & FWA00002399
- Conditions
- Dengue Vaccination Strategy Evaluation, Transmission Modeling of Dengue, Public Health Impact of Vaccination
- Study type
- Observational
- Recruitment status
- Active, not recruiting
- Enrolment
- 220 participants (estimated)
- Lead sponsor
- Fudan UniversityUniversity, hospital or other
- Study start
- 1 May 2025 (actual)
- Primary completion
- 1 May 2026 (actual)
- Study completion
- 1 May 2027 (estimated)
- First posted
- 3 Oct 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study is a collaboration between the School of Public Health at Fudan University and the Xishuangbanna Center for Disease Control and Prevention in Yunnan Province, China. It aims to evaluate the public health impact of dengue vaccination strategies using dynamic transmission models. By simulating different vaccination scenarios, the study will assess the potential effectiveness and public health benefits of dengue vaccine introduction, providing scientific evidence to support local dengue prevention and control efforts.
Study design
- Observational model
- Ecologic or community
- Time perspective
- Cross-sectional
Who may qualify
- Ages
- 3 years and older
- Sex
- All
- Age groups
- Child, Adult, Older adult
- Study population
- Residents of Jinghong City, Xishuangbanna Prefecture, aged 3 years and older, selected across eight age groups for serological investigation of dengue virus exposure.
Key inclusion criteria (4 listed)
- Resident of Jinghong City, Xishuangbanna Prefecture
- Aged 3 years and above
- Able and willing to provide informed consent (or have legal guardian consent for minors)
- Available for blood sample collection between May and August 2025
Key exclusion criteria (2 listed)
- Individuals with bleeding disorders or other contraindications to blood draw
- Individuals currently diagnosed with acute dengue infection
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Dengue Virus Serological Response (IgM and IgG Antibody Levels)
Time frame: From blood sample collection to the completion of laboratory analysis of dengue serology, serotype identification, and whole genome sequencing, from May to August 2025
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 9 Sep 2026.
- Individual participant dataSharing planned: Undecided
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Dengue Vaccination Strategy Evaluation and Transmission Modeling of Dengue, run by Fudan University at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 9 Sep 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Dengue Virus Serological Response (IgM and IgG Antibody Levels) (time frame: From blood sample collection to the completion of laboratory analysis of dengue serology, serotype identification, and whole genome sequencing, from May to August 2025). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 9 Sep 2026.